Primates

, Volume 19, Issue 2, pp 371–378 | Cite as

Antithrombin III activity in baboons

  • Milka M. Montiel
  • David L. McGlasson
Short Communications
  • 18 Downloads

Abstract

The antithrombin III-heparin cofactor activity of 65 baboons and 130 healthy human subjects was measured. The results indicate that antithrombin III-heparin cofactor activity is significantly lower in baboons than in humans.

The increased activity of the coagulation system of baboon is coupled with decreased antithrombin III-heparin cofactor activity. In humans each of these changes is associated with increased risk of thrombosis, but the baboon has a very low risk of developing thrombosis. Other factors probably balance the coagulation-coagulation inhibition systems in baboons.

Keywords

Human Subject Animal Ecology Antithrombin Inhibition System Coagulation System 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abildgaard, U., 1967. Purification of two progressive antithrombins of human plasma.Scand, J. Chin. Lab. Invest., 19: 190–195.Google Scholar
  2. ———— &O. Egeberg, 1968. Thrombin inhibitory activity of fractions obtained by gel filtration of Antithrombin III deficient plasma.Scand. J. Haemat., 5: 115–157.Google Scholar
  3. ————,M. K. Fagerhol, &O. Egeberg, 1970. Comparison of progressive antithrombin activity and the concentrations of three thrombin inhibitors in human plasma.Scand. J. Clin. Lab. Invest., 26: 349–354.PubMedGoogle Scholar
  4. ————,K. Gravem, &H. C. Godal, 1970. Assay of progressive antithrombin in plasma.Thromb. Diath. Haemorrh., 24: 224–229.PubMedGoogle Scholar
  5. Abildgaard, C. F., J. Harrison, &C. A. Johnson, 1971. Comparative study of blood coagulation in nonhuman primates.J. Appl. Physiol., 30: 400–405.PubMedGoogle Scholar
  6. Astrup, T. &S. Darling, 1942. Measurement and properties of antithrombin.ACTA Physiol. Scand., 4: 293–308.Google Scholar
  7. Biggs, R., K. W. E. Denson, R. Akman, R. Barrett, &M. Hadden, 1970. Antithrombin III, antifactor Xa and Heparin.Brit. J. Haemat., 19: 283–305.PubMedGoogle Scholar
  8. ———— &R. G. MacFarlane, 1962.Human Blood Coagulation and Its Disorders. 3rd ed., Blackwell Scientific Publications, Oxford.Google Scholar
  9. Cohen, A. B., 1973. Mechanism of action of α-1-antitrypsin.J. Biol. Chem., 248: 7055–7959.PubMedGoogle Scholar
  10. Damus, P. S., M. Hicks, &R. D. Rosenberg, 1973. A generalized view of heparin's anticoagulant action.Nature, 246: 355–357.PubMedCrossRefGoogle Scholar
  11. Denson, K. W. E., 1961. The specific assay of Prower-Stuart factor and factor VII.Acta. Haematologia, 25: 105–120.Google Scholar
  12. Egeberg, O., 1965. Inherited antithrombin deficiency causing thrombopathia.Thromb. Diath. Haemorrh., 13: 516–530.PubMedGoogle Scholar
  13. Finlayson, R., 1962. Vascular disease in captive animals. In:Symposium of the Zoological Society of London, Vol. 11, Academic Press, London, pp. 99–106.Google Scholar
  14. ————,C. Symons, &R. N. T. W. Fienness, 1962. Atherosclerosis: A comparative study.Brit. Med. J., 5277: 501–507.PubMedGoogle Scholar
  15. Fowell, A. H., 1955. Turbidimetric method of fibrinogen assay.Amer. J. Clin. Path., 25: 340–342.Google Scholar
  16. Ganrot, P. O., 1967. Inhibition of plasmin activity by α2-macroglobulin.Clin. Chim. Acta., 16: 328–330.PubMedCrossRefGoogle Scholar
  17. Greig, H. B. W. &M. Notelowitz, 1975. Natural oestrogens and antithrombin-III levels.Lancet, 2(15): 412–413.Google Scholar
  18. Gruenberg, J. C., R. C. Smallridge, &R. D. Rosenberg, 1975. Inherited antithrombin III deficiency causing mesenteric venous infarction.Annals of Surg., 181: 791–794.Google Scholar
  19. Hampton, J. W. &C. Matthews, 1966. Similarities between baboon and human blood clotting.J. Appl. Phys., 21: 1713–1716.Google Scholar
  20. Hardisty, R. M. &J. C. Macpherson, 1962. One stage factor VIII (antihaemophilia globulin) assay and its use on venous and capillary plasma.Thrombosis & Diathesis Hemorrh., 7(8): 216–229.Google Scholar
  21. Harpel, P. C., N. W. Moesesson, &N. R. Cooper, 1975. Studies in the structure and function of α2-macroglobulin and C1-inactivator. In:Proteases and Biological Control,E. Reich,D. Rifkin, &E. Shaw (eds.), Cold Spring Harbor Lab, New York, pp. 387–404.Google Scholar
  22. Hartley, B. S., 1960. Proteolytic enzymes. In:Ann. Rev. Biochem.,J. M. Luck,F. W. Allen, &G. Mackinney (eds.), Vol. 29, Ann. Reviews Inc., Palo Alto, pp. 45–72.Google Scholar
  23. Hawkey, C., 1974. The relationship between blood coagulation and thrombosis and atherosclerosis in man, monkeys and carnivores.Thromb. Diath. Haemorrh., 31: 103–118.PubMedGoogle Scholar
  24. ———— &C. Symons, 1968. A comparative study of blood coagulation in human and nonhuman primates. In:Proc. 2nd Int. Congr. Primatol., Atlanta, Ga., 1968, Vol. 2, Karger, Basel & N. Y., pp. 86–94.Google Scholar
  25. Hensen, A. &E. A. Loeliger, 1963. Antithrombin III assay.Thromb. Diath. Haemorrh., Suppl 1: 1–84.Google Scholar
  26. Houghie, C., 1972. Methods for estimating fibrinogen concentrations. In:Hematology,W. J. Williams, E. Beutler, A. J. Ersler, & R. W. Rundles (eds.), pp. 1407–1408.Google Scholar
  27. Kaulla, E. von &K. N. von Kaulla, 1967. Antithrombin III and diseases.Amer. J. Clin. Path., 48: 69–80.Google Scholar
  28. ———— & ————, 1972. Deficiency of antithrombin III activity associated with hereditary thrombosis tendency.J. Med., 3: 349–358.Google Scholar
  29. Koerker, D. J., L. A. Harker, &C. J. Goodner, 1975. Effects of somatostatin on hemostasis in baboons.New Eng. J. Med., 293: 475–483.Google Scholar
  30. Lanchanton, G. F., M. L. Plesset, &J. A. Friedmann, 1960. Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin.Proc. Soc. Exp. Biol. Med., 121: 444–449.Google Scholar
  31. Meer, J. van der, E. A. Stoepman-van Dalen, &J. M. S. Jansen, 1973. Antithrombin III deficiency in a Dutch family.J. Clin. Path., 26: 532–538.PubMedGoogle Scholar
  32. Miller-Andersson, M., H. Borg, &L. O. Andersson, 1974. Purification of antithrombin III by affinity chromatography.Thromb. Res., 5: 439–452.CrossRefGoogle Scholar
  33. Nye, S. W., J. B. Graham, &K. M. Brinkhaus, 1962. Activated partial thromboplastin time.Amer. J. Med. Sci., 243: 279.PubMedGoogle Scholar
  34. Pena, A. de la & J. W. Goldziehr, 1967. Clinical parameters of the normal baboon.The Baboon In Med. Res., pp. 379–389.Google Scholar
  35. Quick, A. J., 1967. Prothrombin time. In:Haemorrhagic Diseases, Kempton, London.Google Scholar
  36. Rinderknecht, H. &M. C. Geokas, 1972. Role for α2-macroglobulin in haemostatic balance.Nature New Biol., 239: 116–117.PubMedGoogle Scholar
  37. Roberts, R. C., W. A. Riesen, &P. K. Hall, 1974. Studies on the quarternary structure of human serum α2-macroglobulin. In:Bayer Symposium V. Proteinase Inhibitors,H. Fritz,H. Tschesche,L. J. Green, &E. Truscheit (eds.), Springer-Verlag, Berlin, p. 63.Google Scholar
  38. Robinson, A. J., P. M. Aggeler, G. P. McNicol, &A. S. Douglas, 1967. An atypical genetical haemorrhagic disease with increased concentration of a natural inhibitor of prothrombin consumption.Brit. J. Haemat., 13: 510.PubMedGoogle Scholar
  39. Rosenberg, J. S. &R. D. Rosenberg, 1975. Advances in the understanding of the anticoagulant function of heparin.Current Therapeutic Res., 18: 66–70.Google Scholar
  40. Rosenberg, R. D., 1975. Actions and Interactions of Antithrombin and Heparin.New Eng. J. Med., 292: 146–150.PubMedGoogle Scholar
  41. ———— &P. S. Damus, 1973. The purification and mechanism of action of human antithrombin-heparin cofactor.J. Biol. Chem., 248: 6490–6505.PubMedGoogle Scholar
  42. Saunders, R., B. J. Dyce, W. E. Vannier, &B. J. Haverback, 1971. The separation of α2-macroglobulin into five components with differing electrophoretic and enzyme-binding properties.J. Clin. Invest., 50: 2376–2383.PubMedGoogle Scholar
  43. Schreiber, A. D., A. P. Kaplan, &K. F. Austen, 1973. Plasma inhibitors of the components of the fibrinolytic pathway in man.J. Clin. Invest., 42: 1394–1401.Google Scholar
  44. Seegers, W. H., 1968. Antithrombin as a proteinase inhibitor.Annals of the N. Y. Academy of Science, 146: 593.Google Scholar
  45. ————,F. R. Cole, C. R. Harmison, &F. C. Monkhouse, 1964. Neutralization of autoprothrombin C activity with antithrombin.Can. J. Biochem., 42: 359–364.PubMedGoogle Scholar
  46. Siegel, S., 1956.Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill Book Co., p. 116.Google Scholar
  47. Steinbuch, M., C. Biatriz, &F. Josso, 1967. α2-macroglobulin as a progressive antithrombin.Nature, 216: 500–501.PubMedGoogle Scholar
  48. Teger-Nilsson, A. C. &B. Blombäck, 1974. Rate of thrombin-fibrinogen reaction in some mammalian species.Thromb. Res., 5: 223–233.PubMedGoogle Scholar
  49. Todd, M. E., E. McDevitt, &E. I. Goldsmith, 1972. Blood-clotting mechanisms of nonhuman primates.J. Med. Primat., 1: 132–141.Google Scholar
  50. Yin, E. T., 1974. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma α2-globulin inhibitor.Thromb. Diath. Haemorrh., 33: 43–50.Google Scholar
  51. ———— &S. Wessler, 1969. Evidence for a naturally occurring plasma inhibitor of activated factor X: Isolation and partial purification.Thromb. Diath. Haemorrh., 21: 398–401.PubMedGoogle Scholar
  52. ————, ————, &P. J. Stoll, 1971. Rabbit plasma inhibitory of the activated species of blood coagulation factor X: Purification and some properties.J. Biol. Chem., 246: 3694–3702.PubMedGoogle Scholar

Copyright information

© Japan Monkey Centre 1978

Authors and Affiliations

  • Milka M. Montiel
    • 1
  • David L. McGlasson
    • 1
  1. 1.Department of PathologyThe University of Texas Health Science CenterSan AntonioU.S.A.

Personalised recommendations